T

Tr1X

Develops cellular immunotherapies for autoimmune diseases

Research Associate 2 - Translational Medicine

Full-TimeUpdated
$88k - $93k+ Discretionary annual target bonus + Incentive stock options
Junior
Bachelor's
San Diego, CA, USA
In PersonPosition is on-site in San Diego, CA.
Biology & BiotechTranslational Research & Bench Biology

About the job

Requirements
  • A bachelor's degree in immunology, cell biology, or a related scientific field is required.
  • At least 2 years of industry or equivalent experience in assay development, immunology, cell biology, or a related field is required; translational or biomarker-focused experience is advantageous.
  • Hands-on experience with flow cytometry-based assays, including sample processing, instrument setup, data acquisition, data analysis, and troubleshooting, is required.
  • Experience maintaining cell cultures on primary human cells is required.
  • Reproducible execution of multiplex immunoassays such as ELISA or MSD, and/or molecular assays, is required.
  • Proficiency with analytical software such as Prism and FlowJo is required.
  • Strong attention to detail and ability to follow standard operating procedures and maintain accurate, real-time electronic lab notebook documentation are required.
  • Ability to prepare clear summaries of experimental design and data is required.
  • Ability to manage multiple tasks and meet project timelines is required.
  • Ability to wear required personal protective equipment and safely conduct experiments is required.
  • Must be legally authorized to work for any employer in the United States.
Responsibilities
  • Process human blood and tissue samples according to standard operating procedures and established workflows.
  • Perform weekly flow cytometry runs, including sample preparation, instrument setup with quality control, compensation and photomultiplier tube adjustments, data acquisition, and troubleshooting.
  • Complete and deliver real-time data analysis, ensuring accuracy, reproducibility, and adherence to assay requirements.
  • Conduct MSD, ELISA, and molecular assays such as digital PCR as needed.
  • Maintain cell cultures and perform cell-based assays.
  • Support assay development, optimization, qualification, and troubleshooting in collaboration with scientists.
  • Prepare concise summaries of experimental design and results and deliver presentations in team settings.
  • Document all activities accurately and in real time using an electronic lab notebook.
  • Contribute to drafting and updating standard operating procedures, method documentation, and controlled forms.
  • Support clinical sample management, including receipt, logging, storage, aliquoting, and preparation for downstream analyses.
  • Maintain detailed documentation, chain of custody, and compliance expectations for clinical samples.
  • Perform routine laboratory upkeep, such as reagent inventory.
  • Perform other responsibilities based on business needs.
Desired Qualifications
  • Experience designing flow cytometry panels is a plus.
  • Experience executing cell-based assays such as mixed lymphocyte reactions is a plus.
  • Familiarity with assay development, qualification, and validation workflows, and knowledge of GxP principles or compliance expectations relevant to clinical sample handling and processing, is a plus.
  • Translational or biomarker-focused experience is ideal.

About the company

Tr1X focuses on cellular immunotherapies for autoimmune and inflammatory diseases. Using a proprietary platform, it creates first-in-class cell therapy products that aim to rebalance the immune system and restore homeostasis, achieving long-term tolerance. The company develops and commercializes these therapies, generating revenue through partnerships, licensing, and direct sales, with a business base in La Jolla, CA. How it works: the core product is a cell therapy designed to modulate immune responses so the body reaches stable immune balance rather than ongoing suppression. This differs from many competitors by emphasizing durable immune tolerance via a proprietary platform and by pursuing partnerships and licensing to bring therapies to healthcare providers and patients. The goal is to deliver durable immune tolerance for autoimmune and inflammatory diseases through first-in-class cell therapies.

Company Size

11-50

Company Stage

Early VC

Total Funding

$125M

Headquarters

San Diego, California

Founded

2018

Get referred to Tr1X

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CIRM approved more than $60 million on June 25, 2026, supporting Tr1X programs.
  • October 14, 2025 financing added $50 million and runway into 2027.
  • ASGCT 2026 oral presentations signaled continued clinical momentum across GvHD, Crohn's, and MS.

What critics are saying

  • TRX103 and TRX319 remain unapproved; FDA efficacy scrutiny arrives before 2027.
  • Crohn's results from NCT06721962 report by January 30, 2027, or credibility slips.
  • No approved product means CIRM and venture cash fund only clinical execution.

What makes Tr1X unique

  • TRX103 delivered dose-dependent persistence and tolerogenic signals at ASGCT 2026.
  • TRX319 combines CD19 targeting with Tr1 regulation for progressive multiple sclerosis.
  • Maria Grazia Roncarolo's Tr1 platform creates off-the-shelf allogeneic regulatory T-cell products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • 401(k) Company Match
  • Flexible Work Hours
  • Stock Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

4%

1 year growth

2%

2 year growth

2%
San Diego Business Journal
Oct 27th, 2025
Tr1X Bio Secures $50M Funding

Tr1X Bio, based in San Diego, received FDA approval for IND status for TRX319, aimed at treating progressive multiple sclerosis. The company secured $50M in financing to support clinical trials for TRX319, set to begin next year. Tr1X's technology, based on research by Dr. Maria Grazia Roncarolo, uses allogeneic cells to treat autoimmune diseases. The company also advances TRX103 for graft vs. host disease and Crohn's disease, backed by an $8M CIRM grant.

GlobeNewswire
Oct 14th, 2025
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into...

Clinical Trial Vanguard
Apr 7th, 2025
TR1X Awarded $8M Grant for TRX103 GvHD Trial

TR1X awarded $8M grant for TRX103 GvHD trial.

Benzinga
Apr 4th, 2025
Tr1X Awarded $8 Million Cirm Grant To Support Trx103 Phase 1/2A Clinical Trial For Graft-Versus-Host Disease

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced "Trix"), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials. The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of RD at Tr1X, with patients enrolling at leading stem cell transplant centers across the country. The trial is designed to treat patients receiving a mismatched or haploidentical transplant with a one-time infusion of TRX103. The Company has reported positive initial persistence and safety data in the first two patient cohorts, with additional data anticipated to be reported in 2025

TMCnet
Apr 4th, 2025
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

Tr1X is developing TRX103 for the treatment of several immune and inflammatory disorders.